Graftide S 360mg Tablet

• Prevention of organ rejection in transplant patients

Like any other medicine, Graftide S 360mg Tablet also has some common to severe side effects. These undesired symptoms observed in the body after taking this injection and usually disappear with time as the body adjusts to the medicine.

Common Side Effects Include:

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Headache
• High blood pressure
• Decreased white blood cell count (neutrophils)
• Bacterial infection
• Fungal infection
• Pneumonia
• Increased uric acid level in blood
• Electrolyte imbalance
• Anxiety
• Breathlessness
• Increased creatinine level in blood
• Anemia (low number of red blood cells)
• Acne
• Muscle pain

However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

• Doctor will decide the dose and duration of Graftide S 360mg Tablet based on the type of transplant you have and other factors such as body weight and age. Swallow the whole tablet with a glass of water as it is an orally available drug.
• This tablet can be taken with or without food but on the fixed time everyday to get better results. Take it exactly as advice by the doctor, don't miss a dose or over dose the medicine.
  
  

• Graftide S 360mg Tablet contains Mycophenolate sodium (360mg) as an active ingredient that belongs to the immunosuppressant class of drugs.
• It works by weakening the body’s immune system and reduces its action to prevent the attack on a transplanted organ or rejection of the transplanted organ.
  
  

• Sanford, M., & Keating, G. M. (2008). Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection. Drugs, 68(17), 2505-2533. https://pubmed.ncbi.nlm.nih.gov/19016576/
• Curran, M. P., & Keating, G. M. (2005). Mycophenolate sodium delayed release: prevention of renal transplant rejection. Drugs, 65(6), 799-805. https://pubmed.ncbi.nlm.nih.gov/15819592/
• Remuzzi, G., Lesti, M., Gotti, E., Ganeva, M., Dimitrov, B. D., Ene-Iordache, B., ... & Ruggenenti, P. (2004). Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. The Lancet, 364(9433), 503-512. https://pubmed.ncbi.nlm.nih.gov/15302193/
• Simeón-Aznar, C. P., Fonollosa-Plá, V., Tolosa-Vilella, C., Selva-O’Callaghan, A., Solans-Laqué, R., & Vilardell-Tarrés, M. (2011). Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clinical rheumatology, 30(11), 1393-1398. https://pubmed.ncbi.nlm.nih.gov/21881859/
• Budde, K., Glander, P., Diekmann, F., Waiser, J., Fritsche, L., Dragun, D., & Neumayer, H. H. (2004). Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert opinion on pharmacotherapy, 5(6), 1333-1345. https://pubmed.ncbi.nlm.nih.gov/15163278/
• Salvadori, M., Holzer, H., De Mattos, A., Sollinger, H., Arns, W., Oppenheimer, F., ... & Hall, M. (2004). Enteric coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novorenal transplant patients. American Journal of Transplantation, 4(2), 231-236. https://pubmed.ncbi.nlm.nih.gov/14974944/